Pharming Group N.V. (AMS:PHARM)

Pharming Group Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	366.48	376.13	297.2	245.32	205.62	198.87
Revenue Growth	7.84%	26.56%	21.15%	19.30%	3.40%	-6.27%
Gross Profit Gross Profit Growth	317.09	330.63	261.8	220.1	188.06	177.73
Operating Income Operating Income Growth	25.35	32.76	-3.59	-21.75	10.37	24
Net Income Net Income Growth	9.3	2.85	-11.84	-10.55	13.67	16
Earnings Per Share EPS Growth	0.01	0.00	-0.02	-0.02	0.02	0.02
EPS Growth	-	-	-	-	-17.39%	-58.18%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Ruconest® Ruconest® Growth	299.58	317.92	252.24	227.13	205.62
Joenja® Joenja® Growth	66.9	58.21	44.96	18.18	-
Total Total Growth	366.48	376.13	297.2	245.32	205.62

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	158.28	179.1	167.89	213.42	207.34	191.92
Total Debt Total Debt Growth	113.3	115.78	112.31	171.55	166.69	161.76
Net Cash (Debt) Net Cash Growth	44.99	63.33	55.58	41.88	40.65	30.16
Net Cash Growth	-	13.94%	32.72%	3.03%	34.76%	-30.18%
Net Cash Per Share Net Cash Per Share Growth	0.06	0.08	0.08	0.06	0.06	0.04

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	35.03	54.71	-1.8	-17.3	22.46	37.84
Capital Expenditures CapEx Growth	-0.66	-0.75	-0.79	-1.44	-1.38	-10.74
Free Cash Flow Free Cash Flow Growth	34.37	53.96	-2.59	-18.74	21.08	27.1
Free Cash Flow Growth	14.02%	-	-	-	-22.21%	-65.68%

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	86.52%	87.90%	88.09%	89.72%	91.46%	89.37%
Operating Margin	6.92%	8.71%	-1.21%	-8.87%	5.04%	12.07%
Pretax Margin	4.32%	3.42%	-2.86%	-4.90%	7.29%	11.60%
Profit Margin	2.54%	0.76%	-3.98%	-4.30%	6.65%	8.04%
FCF Margin	9.38%	14.35%	-0.87%	-7.64%	10.25%	13.63%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 16, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	89.72	402.37	-	-	55.27	35.75
Forward PE	62.20	60.69	60.69	170.09	28.96	16.47
P/FCF Ratio	23.38	21.26	-	-	35.85	21.10
PS Ratio	2.19	3.05	2.19	3.11	3.68	2.88

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 16, 2026

Data Sources Report a data error